Profile data is unavailable for this security.
About the company
WAKAMOTO PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the manufacture and sale of ethical drugs such as gastrointestinal drugs and non-prescription drugs. The Company operates through four business segments. The Pharmaceuticals segment is involved in the manufacture and sale of innovator drugs, generic drugs and optiaid series supplements mainly in the ophthalmic field, as well as the commission of production and the sale of diagnostic drugs and raw materials in Japan. The Healthcare segment sales its core product Kawakami Wakamoto, the Avantbise series of medicated toothpastes that promote bad breath prevention based on evidence and Avantbise Oral Tablet mainly in the mail order business. The International segment is involved in the business related to the export of products and raw materials mainly in Asia and Europe, as well as the new license in and out business. The Real Estate Leasing segment is involved in the rental business of Coredo Muromachi.
- Revenue in JPY (TTM)7.74bn
- Net income in JPY108.96m
- Incorporated1933
- Employees274.00
- LocationWakamoto Pharmaceutical Co Ltd2-2-2, Nihombashihon-choCHUO-KU 103-8330JapanJPN
- Phone+81 332790371
- Fax+81 332796450
- Websitehttps://www.wakamoto-pharm.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Renascience Inc | 194.17m | -258.34m | 4.53bn | 4.00 | -- | 2.82 | -- | 23.31 | -20.32 | -20.32 | 15.27 | 126.40 | 0.089 | -- | -- | 48,541,250.00 | -11.84 | -- | -12.49 | -- | 85.31 | -- | -133.05 | -- | -- | -- | 0.1814 | -- | 93.11 | -- | 23.07 | -- | -- | -- |
| Immuno-Biological Laboratories Co., Ltd. | 816.70m | 186.69m | 4.64bn | 57.00 | 24.84 | 3.67 | -- | 5.68 | 20.05 | 20.05 | 87.69 | 135.86 | 0.535 | 0.9358 | 4.53 | 14,328,090.00 | 12.23 | -13.97 | 14.68 | -16.39 | 63.34 | 57.73 | 22.86 | -39.23 | 3.65 | -- | 0.1572 | -- | 2.78 | 0.8924 | 164.44 | -- | -- | -- |
| MEDRx Co Ltd | 22.57m | -770.66m | 4.87bn | 22.00 | -- | 2.28 | -- | 215.60 | -20.97 | -20.97 | 0.6128 | 47.84 | 0.0143 | 0.00 | 4.22 | 1,025,955.00 | -48.80 | -58.15 | -50.27 | -62.23 | 100.00 | 95.70 | -3,414.38 | -1,526.17 | 43.57 | -- | 0.00 | -- | -50.35 | 28.60 | 16.04 | -- | -55.29 | -- |
| Delta-Fly Pharma Inc | 0.00 | -1.43bn | 5.12bn | 13.00 | -- | 4.15 | -- | -- | -197.24 | -197.24 | 0.00 | 149.78 | 0.00 | -- | -- | 0.00 | -120.07 | -67.70 | -141.25 | -72.02 | -- | -- | -- | -877.69 | -- | -243.15 | 0.00 | -- | -- | -- | -7.57 | -- | -9.04 | -- |
| Liberta Co Ltd | 7.39bn | -7.04m | 5.87bn | 118.00 | -- | 4.04 | 40.51 | 0.794 | -1.17 | -1.17 | 1,243.64 | 241.33 | 1.20 | 2.67 | 7.65 | 62,643,520.00 | -0.1068 | 3.75 | -0.2169 | 6.42 | 38.24 | 41.81 | -0.0891 | 2.37 | 0.8247 | 3.15 | 0.6948 | 35.67 | 6.77 | 9.76 | -2.77 | -12.85 | 23.12 | -- |
| COSMO BIO COMPANY, LIMITED | 9.46bn | 408.00m | 6.24bn | 155.00 | 14.74 | 0.6757 | 10.98 | 0.6595 | 69.94 | 69.94 | 1,620.67 | 1,525.81 | 0.8484 | 6.09 | 2.87 | 61,000,000.00 | 3.80 | 5.62 | 4.54 | 6.72 | 33.82 | 37.40 | 4.48 | 6.23 | 5.15 | -- | 0.0021 | 33.53 | -2.23 | 5.16 | -14.51 | 11.20 | -8.03 | 16.47 |
| NIPPON CHEMIPHAR CO., LTD. | 30.75bn | -180.00m | 6.83bn | 887.00 | -- | 0.3132 | 5.34 | 0.222 | -49.89 | -49.89 | 8,520.20 | 5,115.78 | 0.6268 | 2.14 | 2.70 | 34,665,160.00 | -0.3689 | 0.7482 | -0.5204 | 1.08 | 25.17 | 30.99 | -0.5887 | 1.13 | 1.53 | -- | 0.4791 | 50.73 | -2.57 | -2.10 | -153.10 | -- | 24.62 | -12.94 |
| Wakamoto Pharmaceutical Co Ltd | 7.74bn | 108.96m | 8.57bn | 274.00 | 78.36 | 0.71 | 16.46 | 1.11 | 3.14 | 3.14 | 222.97 | 346.51 | 0.4971 | 2.09 | 2.57 | 28,242,430.00 | 0.70 | -2.28 | 0.8046 | -2.64 | 46.52 | 51.00 | 1.41 | -3.97 | 3.85 | -- | 0.0083 | -- | -10.65 | -6.35 | -21.19 | -- | 4.93 | -- |
| Solasia Pharma KK | 408.00m | -1.18bn | 8.91bn | 24.00 | -- | 4.10 | -- | 21.84 | -6.96 | -6.96 | 2.40 | 10.01 | 0.1432 | 2.01 | 3.06 | 17,000,000.00 | -41.50 | -48.57 | -53.67 | -58.83 | 51.23 | 71.01 | -289.71 | -300.89 | 1.68 | -400.00 | 0.2327 | -- | -43.50 | 14.18 | 56.36 | -- | -- | -- |
| K Pharma Inc | 500.00m | -221.98m | 9.04bn | 15.00 | -- | 3.15 | -- | 18.08 | -18.94 | -18.94 | 43.04 | 247.43 | 0.2095 | 4.49 | -- | 33,333,330.00 | -9.30 | -- | -9.83 | -- | 91.00 | -- | -44.40 | -- | 42.60 | -- | 0.00 | -- | -- | -- | 166.34 | -- | -- | -- |
| Perseus Proteomics Inc | 100.40m | -1.10bn | 10.08bn | 25.00 | -- | 5.84 | -- | 100.35 | -93.74 | -93.74 | 8.52 | 117.15 | 0.0471 | 3.35 | 8.55 | 4,016,080.00 | -51.85 | -41.34 | -54.94 | -43.43 | 87.33 | 91.72 | -1,100.04 | -891.26 | 12.77 | -- | 0.00 | -- | 6.58 | -18.31 | -40.34 | -- | 60.30 | -- |
| Kohjin Bio Co Ltd | 4.77bn | 384.98m | 10.89bn | 159.00 | 23.08 | 3.20 | 15.90 | 2.28 | 92.30 | 92.30 | 1,122.07 | 666.48 | -- | -- | -- | 30,000,600.00 | -- | -- | -- | -- | 39.44 | -- | 8.07 | -- | 1.14 | -- | 0.4249 | -- | 0.5715 | -- | -53.61 | -- | -- | -- |
| CanBas Co Ltd (Parent) | 0.00 | -1.09bn | 11.63bn | 12.00 | -- | 3.88 | -- | -- | -64.47 | -64.47 | 0.00 | 166.10 | 0.00 | -- | -- | 0.00 | -43.91 | -65.86 | -45.99 | -79.11 | -- | -- | -- | -1,094.10 | -- | -- | 0.00 | -- | -- | -- | -45.41 | -- | -- | -- |
| Oncolys Biopharma Inc | 28.04m | -1.98bn | 12.47bn | 34.00 | -- | 6.88 | -- | 444.67 | -107.77 | -107.77 | 1.52 | 84.14 | 0.0127 | 0.00 | 0.1476 | 824,647.10 | -89.46 | -45.75 | -101.52 | -51.86 | 100.00 | 60.46 | -7,058.44 | -233.66 | 8.82 | -- | 0.1416 | -- | -93.54 | -17.86 | -68.72 | -- | 28.18 | -- |
| ReproCell Inc | 2.43bn | -31.42m | 12.85bn | 96.00 | -- | 1.48 | 2,254.74 | 5.29 | -0.3466 | -0.3466 | 28.34 | 93.45 | 0.2788 | 5.41 | 5.60 | 25,279,340.00 | -0.3609 | -7.35 | -0.3932 | -8.00 | 46.19 | 39.83 | -1.29 | -27.16 | 10.54 | -- | 0.00 | -- | -17.83 | 17.39 | 89.71 | -- | 13.27 | -- |
Data as of Jul 26 2024. Currency figures normalised to Wakamoto Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY
1.65%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 31 May 2024 | 219.90k | 0.63% |
| Nikko Asset Management Co., Ltd.as of 05 Jul 2024 | 106.50k | 0.31% |
| Daiwa Asset Management Co. Ltd.as of 28 Jun 2024 | 99.50k | 0.29% |
| BlackRock Japan Co. Ltd.as of 04 Jul 2024 | 57.80k | 0.17% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Jul 2024 | 45.80k | 0.13% |
| Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 19 Feb 2024 | 16.10k | 0.05% |
| Asset Management One Co., Ltd.as of 04 Jul 2024 | 13.80k | 0.04% |
| Amundi Asset Management SA (Investment Management)as of 03 Jul 2024 | 6.88k | 0.02% |
| Nissay Asset Management Corp.as of 21 Feb 2023 | 5.40k | 0.02% |
| Norinchukin Zenkyoren Asset Management Co., Ltd.as of 04 Jul 2024 | 4.30k | 0.01% |
More ▼
Data from 31 Mar 2024 - 18 Jul 2024Source: FactSet Research Systems Inc.
